{
    "nct_id": "NCT05984277",
    "official_title": "A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).",
    "inclusion_criteria": "* Histologically or cytologically documented squamous or non-squamous NSCLC.\n* Stage IV NSCLC (according to Version 8 of the IASLC Staging Manual in Thoracic Oncology 2016), not amenable to curative surgery or radiation.\n* Absence of sensitizing EGFR mutations and ALK and ROS1 rearrangements.\n* Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted first-line therapies.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant. Rare subtypes are excluded.\n* Spinal cord compression.\n* Symptomatic brain metastases. Brain metastases may be treated or untreated, but participants must be asymptomatic and off steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of whole brain radiotherapy and study enrollment.\n* History of another primary malignancy except for:\n\n  1. Malignancy treated with curative intent with no known active disease â‰¥ 2 years before the first dose of study intervention and of low potential risk for recurrence.\n  2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  3. Adequately treated carcinoma in situ without evidence of disease.\n* As judged by the investigator, any condition that would interfere with evaluation of the study intervention or interpretation of participant safety or study results.",
    "miscellaneous_criteria": "Key"
}